| Similar Articles |
|---|
 |
The Motley Fool
December 23, 2003
David Nierengarten |
An Undervalued Biotech Nabi Biopharmaceuticals has revenues and a pipeline. Is it undervalued?   |
BusinessWeek
April 12, 2004
Catherine Arnst |
Killer Staph Is Hitting The Streets For the past 30 years, hospitals have been battling a mutant form called methicillin-resistant S. aureus (MRSA) that is resistant to penicillin-related antibiotics and is especially lethal. Now it's showing up in the general population. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
The Motley Fool
August 9, 2010
Luke Timmerman |
Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources. |
The Motley Fool
July 19, 2011
Brian Orelli |
Free Cash, But Be Careful Nabi trades below today's cash, but maybe not next years. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Nursing
May 2010
Debra Castner |
Understanding the stages of chronic kidney disease This article will help you to recognize CKD and understand its stages so you can help your patient to modify risk factors, prevent further kidney damage, and manage complications. First, consider the scope of the problem. |
Pharmaceutical Executive
June 1, 2014
Jill Wechsler |
Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D. |
The Motley Fool
November 17, 2009
Brian Orelli |
This Partnership Is Smoking! Glaxo and Nabi team up for smokers who want to quit. Let's just hope they don't flame out in phase 3 trials. |
The Motley Fool
September 29, 2004
Charly Travers |
Nabi Stamps Out Smoking A nicotine vaccine looks to help smokers kick the habit. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Pharmaceutical Executive
November 1, 2013
William Looney |
Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
American Family Physician
July 1, 2004
Lo Re & Gluckman |
Travel Immunizations The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before trip departure, and current knowledge of the epidemiology of vaccine-preventable diseases. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
Chemistry World
December 6, 2012
Andrew Turley |
Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
American Family Physician
December 1, 2002
Sanford R. Kimmel |
Vaccine Adverse Events: Separating Myth from Reality Vaccines have turned many childhood diseases into distant memories in industrialized countries. However, questions have been raised about the safety of some vaccines because of rare but serious adverse effects that have been attributed to them. |
Nursing Management
March 2010
Becker & Schmidtke |
All along the watchtower: Suicide risk screening, a pilot study Patients will continue to die if healthcare organizations don't take action and appropriately assess patients at risk for suicide in general hospitals. |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note. |
The Motley Fool
February 2, 2006
Brian Gorman |
Cambrex in a Crunch The drug manufacturer is suffering despite positive macro trends. For now, investors shouldn't expect much from Cambrex. |
CIO
October 29, 2015
Martha Heller |
Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies. |
Scientific American
January 2007 |
Meet Resistance Head-On With resistance to antibiotics growing at an alarming pace among pathogenic bacteria, Americans must become more aggressive with regard to early intervention in the processes that foster resistance. |
Pharmaceutical Executive
September 1, 2012
Al Topin |
Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty. |
Pharmaceutical Executive
January 1, 2013
Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
Pharmaceutical Executive
February 1, 2007
Jill Wechsler |
Washington Report: Bundled Together Democrats and Republicans are making waves over whether government drug-pricing policies also raise concerns about drug safety and treatment practices. |
BusinessWeek
July 25, 2005
Catherine Arnst |
O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge. |
Chemistry World
March 17, 2011
Hepeng Jia |
International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
InternetNews
June 3, 2010 |
UofL Web Site Exposes Patients' Personal Info A doctor at the University of Louisville Hospital set up an internal Web site and data base to track and monitor kidney dialysis patients. The problem is the site wasn't password protected. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
